1. Dipyridamole and vascular healing following stent implantation
- Author
-
Trevor Simard, Richard Jung, Pietro Di Santo, Alisha Labinaz, Spencer Short, Pouya Motazedian, Shan Dhaliwal, Dhruv Sarma, Adil Rasheed, F. Daniel Ramirez, Michael Froeschl, Marino Labinaz, David R. Holmes, Mohamad Alkhouli, and Benjamin Hibbert
- Subjects
dipyridamole ,neointima ,in-stent restenosis (ISR) ,adenosine ,adenosine receptor 2B ,optical coherence tomograhy (OCT) ,Diseases of the circulatory (Cardiovascular) system ,RC666-701 - Abstract
IntroductionPatients undergoing coronary stent implantation incur a 2% annual rate of adverse events, largely driven by in-stent restenosis (ISR) due to neointimal (NI) tissue proliferation, a process in which smooth muscle cell (SMC) biology may play a central role. Dipyridamole (DP) is an approved therapeutic agent with data supporting improved vascular patency rates. Pre-clinical data supports that DP may enact its vasculoprotective effects via adenosine receptor-A2B (ADOR-A2B). We sought to evaluate the efficacy of DP to mitigate ISR in a pre-clinical rabbit stent model.Methods & Results24 New Zealand White Rabbits were divided into two cohorts—non-atherosclerosis and atherosclerosis (n = 12/cohort, 6 male and 6 female). Following stent implantation, rabbits were randomized 1:1 to control or oral dipyridamole therapy for 6 weeks followed by optical coherence tomography (OCT) and histology assessment of NI burden and stent strut healing. Compared to control, DP demonstrated a 16.6% relative reduction in NI volume (14.7 ± 0.8% vs. 12.5 ± 0.4%, p = 0.03) and a 36.2% relative increase in optimally healed stent struts (37.8 ± 2.8% vs. 54.6 ± 2.5%, p
- Published
- 2023
- Full Text
- View/download PDF